[{"id":"d6f4d9db-9fa8-4c27-a1fe-5ae416df1f5d","acronym":"","url":"https://clinicaltrials.gov/study/NCT02339168","created_at":"2021-04-26T09:52:48.407Z","updated_at":"2025-02-25T15:33:19.366Z","phase":"Phase 1","brief_title":"Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer","source_id_and_acronym":"NCT02339168","lead_sponsor":"University of California, Davis","biomarkers":" TNFRSF11A","pipe":"","alterations":" ","tags":["TNFRSF11A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xtandi (enzalutamide) • metformin"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 06/22/2016","start_date":" 06/22/2016","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2024-05-08"},{"id":"88a55a61-38e3-4292-be29-cd8c332d6d99","acronym":"","url":"https://clinicaltrials.gov/study/NCT01951586","created_at":"2021-10-25T18:54:29.396Z","updated_at":"2024-07-02T16:36:22.500Z","phase":"Phase 2","brief_title":"Denosumab in Combination With Chemotherapy as First-line Treatment of Metastatic Non-small Cell Lung Cancer","source_id_and_acronym":"NCT01951586","lead_sponsor":"Amgen","biomarkers":" TNFRSF11A • TNFSF11","pipe":"","alterations":" ","tags":["TNFRSF11A • TNFSF11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • carboplatin • Prolia (denosumab) • zoledronic acid"],"overall_status":"Completed","enrollment":" Enrollment 226","initiation":"Initiation: 12/31/2013","start_date":" 12/31/2013","primary_txt":" Primary completion: 07/29/2016","primary_completion_date":" 07/29/2016","study_txt":" Completion: 11/28/2017","study_completion_date":" 11/28/2017","last_update_posted":"2021-10-25"},{"id":"329996b5-121a-4160-83d8-620215815878","acronym":"GeparX","url":"https://clinicaltrials.gov/study/NCT02682693","created_at":"2021-01-18T13:04:55.606Z","updated_at":"2025-02-25T14:00:55.583Z","phase":"Phase 2","brief_title":"Denosumab as an add-on Neoadjuvant Treatment (GeparX)","source_id_and_acronym":"NCT02682693 - GeparX","lead_sponsor":"German Breast Group","biomarkers":" HER-2 • ER • PGR • TNFRSF11A","pipe":" | ","alterations":" HER-2 positive • ER negative","tags":["HER-2 • ER • PGR • TNFRSF11A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • carboplatin • Perjeta (pertuzumab) • albumin-bound paclitaxel • cyclophosphamide • epirubicin • Prolia (denosumab) • cyclophosphamide intravenous"],"overall_status":"Completed","enrollment":" Enrollment 780","initiation":"Initiation: 02/13/2017","start_date":" 02/13/2017","primary_txt":" Primary completion: 12/31/2019","primary_completion_date":" 12/31/2019","study_txt":" Completion: 12/31/2020","study_completion_date":" 12/31/2020","last_update_posted":"2021-02-02"},{"id":"2bddecae-a53c-4f25-8868-153d61b946fa","acronym":"","url":"https://clinicaltrials.gov/study/NCT03629717","created_at":"2021-04-26T09:52:58.772Z","updated_at":"2024-07-02T16:36:46.012Z","phase":"Phase 1","brief_title":"RANKL Inhibition and Breast Tissue Biomarkers","source_id_and_acronym":"NCT03629717","lead_sponsor":"Washington University School of Medicine","biomarkers":" TNFRSF11A","pipe":"","alterations":" ","tags":["TNFRSF11A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Prolia (denosumab)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 06/01/2018","start_date":" 06/01/2018","primary_txt":" Primary completion: 12/03/2018","primary_completion_date":" 12/03/2018","study_txt":" Completion: 12/03/2018","study_completion_date":" 12/03/2018","last_update_posted":"2020-04-14"}]